Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Member News
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Related or similar articles
.avif)
April 29, 2024
Lab Space Boston: Navigating Opportunities and Challenges
Hello, fellow science enthusiasts! If you're on the hunt for the perfect laboratory space in greater Boston and Cambridge, you've come to the right place. As experts in the field, we at Labshares know a thing or two about navigating the opportunities
Labshares News
November 2, 2018
Newton's First Life Sciences Incubator Set To Expand
Longtime biotech executive Jeff Behrens ventured out of the C-Suite earlier this year, opening the first life sciences-focused incubator in Newton. Now he's expanding the project amid broader demand for shared lab space.
Labshares News
